ClinicalTrials.gg
RecruitingNCT04751435IMAGINEUpdated Oct 5, 2026

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

An interventional study of Cognitive interview and LCAM intervention in Educational Materials for Genetic Testing, Breast Cancer and Ovarian Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Oct 1, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center — 47 open to participants now, 98 under way, 3 of them phase 3. Breast Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
11th of 156
445 · median 51
Started
2021
with 11 others
No phase
60 of 253
13 open now
Primary completion
2027-08
later than 49 of 97 live
Registered
196th of 253
by date

Among the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 11th largest by planned enrollment of the 156 interventional ones that give a count, is one of 12 that started in 2021, is one of 60 with no phase, reaches primary completion later than 49 of the 97 other live ones, and was the 196th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

47 of the 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 4 countries. Recruiting first, the newest first:

42 more — sign in →

By country, each count listing its studies:

All 47 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 253 studies in Breast Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or multiple genes at the same time. Genetic testing may change the options for treating people with certain types of cancer. For example, some medications are more helpful for the treatment of cancer in people with certain gene changes (mutations).

The researchers are doing this study to develop new educational materials about genetic testing for people who speak different languages and have diverse cultural and educational backgrounds. During the study, the staff will interview participants with diverse cultural and educational backgrounds and ask them to review a sample of the educational materials that have been developed so far. Participants will give their opinions on these materials, and the researchers will use participants' feedback to improve the materials.

Read the detailed description

The objective of this proposal is to develop, test and evaluate a mainstreaming (LCAM) model for hereditary cancer multigene panel testing (MGPT) among many different types of cancer patients. The central hypothesis is that this LCAM genetic testing model will lead to better patient decision-making, psychosocial, and behavioral outcomes than a traditional model of genetic services represented by our standard-of-care arm. In Phase 1, the researchers will first conduct formative research including transcreation and cognitive interviewing to adapt our existing educational materials (brochure and video) and clinical communication materials (clinic visit summary and family dissemination messaging) for the LCAM model to be useful for patients of many different backgrounds. In Phase 2, the researchers will conduct a randomized clinical trial (RCT) to test and evaluate effects of the LCAM model for hereditary cancer MGPT as compared to standard-of-care among the patients treated at local community hospitals. Patients diagnosed with breast, colorectal, ovarian, pancreatic, or prostate cancer will be offered hereditary cancer MGPT through either: i) standard-of-care wherein in-depth pre-test and post-test genetic counseling are provided via telegenetics (videoconferencing), or ii) LCAM intervention wherein patients receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials. Participants will be followed prospectively and will complete assessments consisting of validated and investigator-designed measures. Phase 2 primary outcomes include genetic test decision satisfaction and genetic counseling satisfaction. Secondary outcomes include additional decision-making, psychosocial, and behavioral outcomes.

For Phase 2, participants will be recruited from our partnering sites, which include Kings County Hospital Center, Queens Cancer Center, Jamaica Hospital Medical Center, and the MSK Ralph Lauren Center for Cancer Care as well via referrals from underserved community sites through the MSK RLCCC network. Study staff will identify eligible patients from review of clinic lists and patient medical records, and will also receive direct study referrals from clinicians located at the partnering sites. Study staff will approach eligible patients in order to describe the study, screen them for eligibility (including assessing language proficiency via self-report and prior experience with cancer genetic counseling/testing), and obtain informed consent and collect their contact information.

03

Conditions studied

  • Educational Materials for Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Pancreatic Cancer
  • Colorectal Cancer

Keywords

  • Educational Materials
  • Genetic Testing
  • Hereditary Cancer
  • Diverse Cancer Patients
  • Colorectal Cancer
  • 20-458
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase 1

  • Age ≥ 18 years as per self-report
  • Current or previous diagnosis of breast, ovarian, pancreatic, or prostate cancer as per self-report
  • Self-identification as Black, Latino, and/or neither Black nor Latino (i.e.,non-Latino, Non black)
  • Fluency in English, Haitian Creole, or Spanish as per self-report (for Spanish, we will attempt to recruit a cohort representing a variety of regions where Spanish is spoken, as informed by current data from participating sites, to achieve neutrality in the language) Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken and reading ability.

Phase 2:

  • Age ≥ 18 years as per the medical record and/or clinician referral
  • Current or previous diagnosis of breast, colorectal, ovarian, pancreatic, or prostate cancer meeting at least one of the applicable criteria for the cancer type as per the medical record and/or clinician referral:
  • Breast cancer criteria:

    • any diagnosis age 65 or younger;
    • diagnosis of triple negative breast cancer at any age;
    • multiple primary breast cancers at any age;
    • under consideration for PARP therapy;
    • any family history (1st, 2nd, or 3rd degree relatives) of ovarian or pancreas cancer, or 1 relative with breast cancer who meets the above criteria, or 2 relatives with breast cancer at any age; or clinician discretion)
  • colorectal cancer
  • Ovarian cancer criteria:
  • invasive ovarian cancer
  • Pancreatic cancer criteria:
  • pancreatic adenocarcinoma
  • Prostate cancer criteria:

    • castrate-resistant, prostate cancer;
    • high-risk prostate cancer (pending pathology definition)
  • Fluency in English, Haitian Creole, or Spanish as per self-report. Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken ability
  • No prior cancer genetic counseling or germline testing for cancer risk as per self-report clinician's note, and/or no clinical documentation

Exclusion criteria

Exclusion Criteria:

Phase 1:

  • Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment.
  • Subjects who indicate level of fluency as "not at all" or "not well".

Phase 2:

  • Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment.
  • Subjects who indicate level of fluency as "not at all" or "not well".
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
445 participants (estimated)

Study arms

  • Experimental
    Cognitive interview intervention for Phase 1

    There is no treatment or intervention for Phase 1 of this study. Participants will be asked to participate in a cognitive interview. This section will be amended to include the Phase 2 intervention information once the Phase 1 portion of the study is complete. The Phase 1 materials developed, and results obtained, will directly be part of and inform the intervention for Phase 2.Phase 2: participants will be randomized to the standard-of-care arm or the LCAM intervention arm.

    Other: Cognitive interview

  • Active comparator
    Standard of care (Phase II only randomization)

    Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics

    Behavioral: Standard of care

  • Active comparator
    LCAM Intervention (Phase II only randomization)

    Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.

    Behavioral: LCAM intervention

Interventions

  • OtherCognitive interview

    Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.

  • BehavioralLCAM intervention

    Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.

  • BehavioralStandard of care

    Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics

06

What researchers measure

Primary outcomes

  1. Number of patients who complete the cognitive interview (Phase I)

    the number of patients who complete the cognitive interview

    Time frame: 1 year

  2. Genetic test decision (Phase II) satisfaction

    is measured with the validated Satisfaction with Decisions scale.

    Time frame: 6 months

  3. Genetic counseling satisfaction (Phase II)

    is measured with the validated Genetic Counseling Satisfaction scale

    Time frame: 6 months

Secondary outcomes

  1. Test uptake (Phase II)

    the number of patients who complete multigene panel testing

    Time frame: 6 months

  2. Knowledge (Phase II)

    measured with items from the validated KnowGene scale (scores range from 0 to 6, higher scores indicate greater knowledge)

    Time frame: 6 months

  3. Empowerment (Phase II)

    measured with the validated Genomics Outcome Scale (scores range from 6 to 30, higher scores indicate greater empowerment)

    Time frame: 6 months

  4. Distress (Phase II)

    measured with the validated Hospital Anxiety and Depression Scale (total scale scores range from 0 to 42, higher scores indicate greater distress)

    Time frame: 6 months

  5. Concerns about genetic testing (Phase II)

    measured with the validated Multidimensional Impact of Cancer Risk Assessment questionnaire (total scale scores range from 0 to 95, higher scores indicate greater concerns about genetic testing)

    Time frame: 6 months

  6. Family communication (Phase II)

    measured with investigator-designed items

    Time frame: 6 months

  7. Family cascade testing (Phase II)

    the number of first-degree relatives who complete genetic testing

    Time frame: 6 months

  8. Intentions to adopt risk management behaviors (Phase II)

    measured with items derived from the Behavioral Risk Factor Surveillance System and National Health Interview Survey

    Time frame: 6 months

  9. Long term engagement and understanding (Phase II)

    measured with investigator-designed items

    Time frame: 6 months

07

Study locations

4 of 4 sites recruiting
  • Kings County Hopsital Center
    Brooklyn, New York 11203, United States
    Recruiting
    • Jason Gonsky, MD · Contact(718) 245-2847
  • Queens Cancer Center of Queens Hospital
    Jamaica, New York 11432, United States
    Recruiting
    • Linda Bulone, RN, OCN, CCRC · Contact(718) 883-2958
  • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
    New York, New York 10035, United States
    Recruiting
    • Jada Hamilton, PhD, MPH · Contact646-888-0049
  • Jamaica Hospital Medical Center (Data Collection Only)
    Richmond Hill, New York 11418, United States
    Recruiting
    • Rosa Nouvini, MD · Contact(718) 206-6000
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Aug 2027, 69 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 69 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
Nov 16, 2021
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
3 inclusion criteria edited, 5 removed
What changed in the criteria
Inclusion criteria
  • EditedColorectalcolorectal cancer criteria:
  • Removedany diagnosis age 50 and below;
  • Removedmismatch repair deficient colorectal cancer;
  • Removedcolorectal cancer at any age with an additional Lynch syndromerelated primary cancer at any age;
  • Removedcolorectal cancer at any age with a 1st or 2nd degree relative with colorectal cancer at/before age 50;
  • Removedcolorectal cancer at any age with 2 or more 1st or 2nd degree relatives with a Lynch syndrome-related cancer at any age
  • Edited° invasive ovarian cancer
  • Edited° pancreatic adenocarcinoma
Oct 1, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 1, 2026
  • AddedTest uptake (Phase II)Time frame: 6 months
  • AddedKnowledge (Phase II)Time frame: 6 months
  • AddedEmpowerment (Phase II)Time frame: 6 months
  • AddedDistress (Phase II)Time frame: 6 months
  • AddedConcerns about genetic testing (Phase II)Time frame: 6 months
  • AddedFamily communication (Phase II)Time frame: 6 months
  • AddedFamily cascade testing (Phase II)Time frame: 6 months
  • AddedIntentions to adopt risk management behaviors (Phase II)Time frame: 6 months
  • AddedLong term engagement and understanding (Phase II)Time frame: 6 months
What changed on Oct 5, 2026
  • DescriptionConcerns about genetic testing (Phase II): how it is measured was reworded
  • DescriptionDistress (Phase II): how it is measured was reworded
  • DescriptionEmpowerment (Phase II): how it is measured was reworded
  • DescriptionKnowledge (Phase II): how it is measured was reworded
across 2 updates, Oct 1, 2026 – Oct 5, 2026
Show all 2 updates
  1. Oct 5, 2026
    Secondary outcomes 4 description edited
    What changed in the outcomes
    • DescriptionConcerns about genetic testing (Phase II): how it is measured was reworded
    • DescriptionDistress (Phase II): how it is measured was reworded
    • DescriptionEmpowerment (Phase II): how it is measured was reworded
    • DescriptionKnowledge (Phase II): how it is measured was reworded
    + 1 other change: verification date
  2. Oct 1, 2026
    Eligibility 3 inclusion criteria edited, 5 removed
    What changed in the criteria
    Inclusion criteria
    • EditedColorectalcolorectal cancer criteria:
    • Removedany diagnosis age 50 and below;
    • Removedmismatch repair deficient colorectal cancer;
    • Removedcolorectal cancer at any age with an additional Lynch syndromerelated primary cancer at any age;
    • Removedcolorectal cancer at any age with a 1st or 2nd degree relative with colorectal cancer at/before age 50;
    • Removedcolorectal cancer at any age with 2 or more 1st or 2nd degree relatives with a Lynch syndrome-related cancer at any age
    • Edited° invasive ovarian cancer
    • Edited° pancreatic adenocarcinoma
    Secondary outcomes 9 added
    What changed in the outcomes
    • AddedTest uptake (Phase II)Time frame: 6 months
    • AddedKnowledge (Phase II)Time frame: 6 months
    • AddedEmpowerment (Phase II)Time frame: 6 months
    • AddedDistress (Phase II)Time frame: 6 months
    • AddedConcerns about genetic testing (Phase II)Time frame: 6 months
    • AddedFamily communication (Phase II)Time frame: 6 months
    • AddedFamily cascade testing (Phase II)Time frame: 6 months
    • AddedIntentions to adopt risk management behaviors (Phase II)Time frame: 6 months
    • AddedLong term engagement and understanding (Phase II)Time frame: 6 months
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04751435
Responsible party
Sponsor
First posted
Feb 12, 2021
Start date
Nov 16, 2021
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Jada Hamilton, PhD, MPH
Contact
hamiltoj@mskcc.org
646-888-0049
Jennifer Hay, PhD
Contact
646-888-0039
Jada Hamilton, PhD, MPH
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion